In the present study, both curcumin and Cur@Hb nanocomposites inhibited vascular mimicry and the expressions of VE-cadherin, twist1 and MMP2, suggesting Cur@Hb might be used as an anti-VM drug for hepatoma. This evidence concerns the gene TWIST1 and hepatocellular carcinoma.